Dehydro aripiprazole, the primary active metabolite of the atypical antipsychotic aripiprazole, is formed via CYP3A4 and CYP2D6 metabolism. It exhibits comparable pharmacological activity and is utilized in neuroscience research for investigating antipsychotic mechanisms in both in vitro and in vivo experimental models.